Loading...
Loading...
ELDN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.0M |
| Operating I/L | -58.7M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.0M |
| Pretax | -58.4M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -58.0M |
Eledon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in developing medicines for autoimmune diseases, amyotrophic lateral sclerosis (ALS), and organ or cell-based transplants. Their lead product candidate, AT-1501, is a humanized monoclonal antibody targeting CD40 Ligand expressed on T cells. It is currently in Phase 2a clinical trials for ALS and Phase 2 clinical trials for islet cell transplantation in type 1 diabetes treatment. Eledon Pharmaceuticals, Inc. generates revenue through the development and potential commercialization of innovative therapies for these medical conditions.
